-

Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Goldman Sachs’ 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 15, 2022. Adam Lenkowsky, Senior Vice President and General Manager, U.S. Commercialization, will answer questions about the company at 9:20 a.m. PT/12:20 p.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company’s presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

CorporateFinancial-News

Contacts

Bristol Myers Squibb
Media: media@bms.com
Investor Relations: investors@bms.cominvestor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Versions
English
$Cashtags
$BMY
Hashtags
#BMS
#BristolMyersSquibb

Contacts

Bristol Myers Squibb
Media: media@bms.com
Investor Relations: investors@bms.cominvestor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years...

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM...

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

PRINCETON, N.J.--(BUSINESS WIRE)--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy....
Back to Newsroom